News
Good News! Wanbangde Pharmaceutical Group has been named to the "Most Promising Growth Enterprise in China's Pharmaceutical Industry" list for the fourth consecutive year!
Date:
15 Jan,2023
Editor’s Note: In 2022, amid the intertwined impacts of unprecedented global changes and a century-spanning pandemic, the world economy faced significant challenges—especially for the pharmaceutical and healthcare industry, which shoulders the dual responsibility of driving economic growth while ensuring national well-being and people’s livelihoods.
China is at a critical historical juncture as it transitions from being a major pharmaceutical manufacturing nation to a global leader in pharmaceutical innovation. How can we stay committed to innovation and build sustainable, forward-moving momentum? How can we seize strategic initiative to drive high-quality development of China’s pharmaceutical and healthcare industry? And how can we strengthen the public health system to better fulfill our responsibilities to the times and our mission to the industry?
In this context, from December 17 to 20, 2022, The 39th National Pharmaceutical Industry Information Conference was grandly held in Shanghai, with this year's event themed "Innovation & Responsibility." By examining development trends from multiple angles—such as the policy environment, innovation ecosystem, global trends, and capital flows—we gain insights into market shifts, identify emerging collaboration models, and drive continuous industry upgrades.
On the afternoon of December 18, the highly anticipated "2022 China's Most Promising Pharmaceutical Companies" list was officially unveiled at the conference. The ranking was developed through rigorous research and analysis of objective data from companies in the pharmaceutical industry, leveraging insights from the New Drug R&D Monitoring Database, the Comprehensive Drug Database, the Hospital Market Analysis System, the China Pharmaceutical Retail Database, interviews with industry experts, and other publicly available sources. A scientific evaluation framework was established, and the final scores were determined by two independent expert panels—the Product Selection Group and the Company Selection Group—each conducting their own comprehensive assessments.
After rigorous evaluation, Wanbangde Pharmaceutical Group Co., Ltd. stood out among numerous pharmaceutical companies across the country. Ranked on the "2022 China's Most Promising Pharmaceutical Companies" list ！
Wanbangde Pharmaceutical Group, founded in 1970, is a high-tech enterprise dedicated to the research, development, manufacturing, and sales of modern Chinese medicines, chemical APIs, and their corresponding formulations.
Being listed for four consecutive years is not only a prestigious honor but also a profound responsibility and powerful motivator. At the forefront of technological innovation, putting people first—moving forward, Wanbangde Pharmaceutical Group will continue to forge ahead with "innovation as our wings," guided by the banner of compassion. We’ll steadily advance our product strategy—centered on natural herbal medicines, with a strong focus on cardiovascular, cerebrovascular, and nervous system drugs, while expanding into respiratory and other therapeutic areas—resolutely striving toward our vision: "Pioneering innovative modern Chinese medicine to enhance public health!"
Related Recommendations